3-year Follow-up of the SCOT RCT: 3-month Oxaliplatin-containing Adjuvant Chemotherapy is Non-inferior to 6 Months of the Same Regimen for Patients with High-risk Stage II and III Colorectal Cancer

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT – Health Technology Assessment (free)

Original Article: 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial – The Lancet Oncology (free)

Source: EvidenceAlerts